Enantigen Therapeutics, OnCore Biopharma deal

HBV company OnCore acquired infectious disease company Enantigen in a cash deal for an undisclosed amount. OnCore gains two HBV programs, an s-antigen secretion inhibitor and a capsid assembly inhibit...